{
  "id": 126785,
  "title": "Merck's anti-TL1A antibody scores a win in hidradenitis suppurativa, fails in SSc-ILD",
  "url": "https://urgent.news/2026/08/04/mercks-anti-tl1a-antibody-scores-a-win-in-hidradenitis-suppurativa",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-04T10:30:21.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/mercks-anti-tl1a-from-prometheus-scores-a-win-in-hidradenitis-suppurativa-but-fails-in-ssc-ild/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Merck said the anti-TL1A antibody at the center of its $10.8 billion Prometheus Biosciences acquisition failed a mid-stage trial for a rare type of lung disease, while also succeeding in a separate mid-stage study for ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}